| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. | IRX-2 (CIN-201) | Cervical Squamous Intraepithelial Neoplasia 3 | Phase 2 | Trial Discontinued | Subcutaneous injection | Oncology |
| Ernexa Therapeutics Inc. | IRX-2 - (INSPIRE) | Head and neck squamous cell cancer | Phase 2b | Trial Discontinued | subcutaneous injection | Oncology |
| Ernexa Therapeutics Inc. | IRX-2 and KEYTRUDA (pembrolizumab) - (BR-202) | Breast Cancer | Phase 2 | Trial Discontinued | IRX-2: subcutaneous KEYTRUDA pembrolizumab: intravenous | Oncology |
| Erytech Pharma S.A. | GRASPA (Eryaspase) | Acute lymphoblastic leukemia (ALL) | BLA Filing | Intravenous | Oncology | |
| Erytech Pharma S.A. | Eryaspase - (Trybeca-1) | Pancreatic cancer | Phase 3 | Intravenous | Oncology | |
| Erytech Pharma S.A. | Hydro-Lido | Hemorrhoids | Phase 2a | Topical | N/A | |
| Erytech Pharma S.A. | Hydro-Lido | Hemorrhoids | Phase 2a | Topical | N/A | |
| Erytech Pharma S.A. | GRASPA (Eryaspase) with gemcitabine and carboplatin chemotherapy - (TRYbeCA-2) | Triple-Negative Breast Cancer (TNBC) | Phase 2/3 | Intravenous | Oncology |